Solid lipid nanoparticles (SLNs) are nanoscale colloidal drug carriers composed of physiological lipids that remain solid at both room and body temperature. They were developed in the early 1990s by R. H. Müller and colleagues to overcome the major limitations of conventional carriers such as liposomes and polymeric nanoparticles, including physical instability, potential toxicity, and difficulties in large-scale production. This review provides a comprehensive evaluation of SLN formulation principles, physicochemical properties, preparation techniques, drug incorporation mechanisms, release kinetics, stability factors, regulatory considerations, clinical translation, and emerging applications. It presents an integrated analysis of the mechanistic, thermodynamic, kinetic, and industrial aspects of SLNs, linking pharmaceutical nanotechnology principles with modern biomedical applications. SLNs offer several advantages, including improved drug stability, controlled and sustained release, enhanced bioavailability, reduced systemic toxicity, and feasibility for industrial-scale manufacturing. Their applications extend across multiple therapeutic areas such as oncology, central nervous system disorders, antimicrobial therapy, gene delivery, and nutraceutical delivery. Although certain challenges remain, particularly polymorphic transitions of lipids and relatively limited drug loading capacity, SLNs continue to represent a promising and versatile nanocarrier platform with significant translational potential, especially in the fields of gene therapy and personalized nanomedicine.